Print Page  |  Close Window

Investor Overview

INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, SUBSYS®, a sublingual Fentanyl spray for breakthrough cancer pain launched in March of 2012, and SYNDROS®, the first and only FDA-approved liquid dronabinol for loss of appetite in AIDS patients and nausea and vomiting caused by anti-cancer medicine (chemotherapy). Please see full prescribing information for SUBSYS® and SYNDROS® including the boxed warning.

Our product pipeline is aimed at addressing conditions with unmet medical needs, such as refractory pediatric epilepsy (including childhood absence epilepsy and infantile spasms), the genetic disorder Prader-Willi syndrome, anorexia-associated weight loss in cancer patients, agitation in Alzheimer's disease, migraine, anaphylaxis (severe allergic reaction), acute pain, opioid dependence and reversal of opioid-induced respiratory depression.

Recent News

Apr 18 2018
INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
PHOENIX, April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronab... 
Apr 02 2018
INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors
PHOENIX, April 02, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of Trudy Vanhove as a new in... 
Mar 19 2018
INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline
PHOENIX, March 19, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement: The company conti... 
see all news

Upcoming Events

There are currently no events scheduled.

see all events